Public Advisory - Recall of one lot of Jamp-Atorvastatin Calcium as some bottles may be labelled as containing 10 mg tablets, but contain 40 mg tablets
OTTAWA, ON, Aug. 27, 2022 /CNW/ -
Summary
Product: Jamp-Atorvastatin Calcium. Some bottles may be labelled as 10 mg tablets (DIN 02504197) but contain 40 mg tablets.
Issue: Health products ? Dosage Health products ? Labelling
What to do: Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. If you are unsure, contact your pharmacist to check if your bottle contains the correct tablets. If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Seek immediate medical attention if you experience serious adverse effects, which may include muscle pain or muscle weakness.
Photos
Affected products
Product
Company
DIN
Lot
Expiry Date
Jamp-Atorvastatin Calcium
10 mg tablets
Jamp Pharma Corporation
02504197
D10776B
06/2023
Jamp-Atorvastatin Calcium
40 mg tablets
Jamp Pharma Corporation
02504219
D10776B
06/2023
Issue
Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.
Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.
Product from the affected lot was sold to pharmacies between May 2022 and August 2022.
Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side.
Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.
Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. 10 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "10" marked on one side and "AT" marked on the other. 40 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "40" marked on one side and "AT" marked on the other.
If you are unsure, contact your pharmacist to check if your bottle of Jamp-Atorvastatin Calcium contains the correct tablets.
If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal.
Seek medical attention immediately if you experience any serious adverse effects from atorvastatin calcium which may include muscle pain or muscle weakness.
Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected], if you have questions about this recall.
Additional information for health care professionals:
Health care professionals, such as pharmacists, should check bottles labelled as Jamp-Atorvastatin Calcium, 10 mg tablets before dispensing to ensure they contain the correct tablets.
Report any unusual packages to the company, and to Health Canada.
Alert / recall type: Public Advisory Category: Health products ? Drugs Published by: Health Canada
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has...
MyAdvisor, a holistic wellness company, is pleased to announce the opening of a new office in Bedford, Pennsylvania. This strategic expansion is driven by the company's sustained growth and commitment...
Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented...
The toxic drug crisis that is now killing an average of 10 Ontarians every day will be the focus of a media conference organized by the Registered Nurses' Association of Ontario (RNAO) to close Nursing Week.
While Nursing Week (May 6-12) is mainly...
Co-founder and CEO, Andrew Mignatti, of healthcare technology company, careviso, spoke at The Third Virtual National Health Care Transparency and No Surprises Act Summit. Mignatti's presentation centered around the existing transparency legislation...
Texas Children's Hospital is pleased to announce the new executive leadership structure at the Texas Children's Heart Center, which has been ranked number one in the nation for pediatric cardiology and heart surgery by U.S. News and World Report for...